The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
|Slideshows|August 2, 2017
Tips for Enhancing Disease-Modifying Therapy Adherence in Multiple Sclerosis
Author(s)Kyla McKay, BSc, PhD Candidate
Adherence is a major concern for clinicians across all disciplines. Even the most effective treatment will not be successful if the patients does not adhere to the prescribed treatment strategy. Inside learn more about the problem and ways to maximize adherence.
Advertisement
Advertisement
Related to this article
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Here's some of what is coming soon to NeurologyLive® this week.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
3
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
4
Congress Passes ACT for ALS Reauthorization, Extending Research Programs
5